Gansu Fuzheng Pharmaceutical Wins Drug Patent Battle
This article was originally published in PharmAsia News
Executive Summary
Gansu Fuzheng Pharmaceutical Technologies and Gansu Xinlanyao Pharmaceutical, which jointly produce Zhenqi Fuzheng Capsule, received a Lunar New Year gift from China's State FDA: the announcement that it has terminated Guizhou Xinbang Pharmaceutical's Zhenqi Fuzheng Capsule production effective from Dec. 31. The two Gansu firms have been offering the capsule since 1993 and secured China's intellectual property rights in 2003. However, Guizhou Xinbang managed to get national approval to produce its "concentrated" version of the drug in Guizhou and Sichuan in 2001. The Gansu partners fought for seven years to regain the protected status of the patented drug, a quest supported by Gansu province's government and drug administration. (Click here for more - Chinese Language)
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.